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TO THE EDITOR
Photodynamic therapy (PDT) is a Food
and Drug Administration-approved pro-
cedure used for the treatment of pre-
cancerous actinic keratosis as well as
superficial skin cancers (Morton et al.,
2008). The treatment is based on the
topical application of a photosensitizing
agent or its metabolic precursor
(e.g., 5-aminolevulinic acid; 5-ALA)
that has preferential uptake by
proliferative/metabolically active cells
(e.g., malignant cells), followed by
exposure of the treated skin to a light
source of a specific wavelength. This
exposure promotes the photosensitizing
agent to generate singlet oxygen and
then other reactive oxygen species,
leading to oxidative stress and cell
death (Dougherty et al., 1998). Several
studies have shown that PDT can cause
immunosuppression in both humans
and mice, but the mechanisms
underlying these effects are not totally
clear (Matthews and Damian, 2010;
Mroz and Hamblin, 2011).
Platelet-activating factor (1-alkyl-2-
acetyl glycerophosphocholine; PAF) is a
lipid-derived mediator with diverse func-
tions. Glycerophosphocholines (GPCs)
from cell membranes can undergo oxi-
dation, resulting in the formation of
oxidized GPCs (Ox-GPCs), which can
act as potent agonists for the PAF recep-
tor (PAF-R) (Konger et al., 2008).
Numerous environmental pro-oxidative
stressors from cigarette smoke to UVB
radiation can induce systemic immuno-
suppression via generation of Ox-GPC
PAF-R ligands (Walterscheid et al.,
2002; Wolf et al., 2006; Zhang et al.,
2008; Yao et al., 2009; Sahu et al.,
2013). Of interest, UVB-generated
PAF-R ligands also augment experi-
mental melanoma tumor growth by
suppressing anti-tumor immunity (Sahu
et al., 2012). Apoptotic cells also express
PAF-R ligands and were shown to pro-
mote the growth of a sub-tumorigenic
inoculum of melanoma cells (Bachi
et al., 2012). The present study was
designed to test the hypothesis that
PAF-R activation mediates PDT-induced
systemic immunosuppression.
First, to evaluate whether PDT pro-
duces PAF-R ligands, we simulated
PDT in the human keratinocyte–
derived cell line HaCaT by incubating
the cells with 5-ALA (1 mM, 4 hours)
and exposing them to a blue light
(415 nm, 10–20 J cm2) source. As
multiple GPC species can act as
PAF-R agonists, we quantified total
PAF-R biochemical activity using PAF-
R-expressing KBP cells that produce
IL-8 when the receptor is activated
(Pei et al., 1998). KBP and PAF-R-
negative KBM cells were exposed for
6 hours to lipid extracts from HaCaT
cells treated with 5-ALA and exposed to
blue light (PDT). The IL-8 pro-
duction was expressed as the %
of normalized lipid extract IL-8
response versus that induced by 100 nM
of the metabolically stable PAF-R agonist
1-hexadecyl-2-N-methylcarbamoyl GPC
(CPAF; see Supplementary Figure S1
online for example of CPAF dose–
response curve). As shown in Figure 1a,
5-ALA plus blue light generated significant
levels of PAF-R ligands, with no percep-
tible effect of 5-ALA or light treatment
alone. The levels of PAF-R ligands
remained elevated for at least 1 hour
post PDT (Figure 1b). Moreover, lipid
extracts from PDT-treated HaCaT cells
also induced intracellular calcium
mobilization responses in KBP cells
loaded with the calcium-sensitive dye
Fura-2 AM, whereas lipid extracts from
sham-treated HaCaT cells resulted in a
negligible response (Supplementary
Figure S2 online). However, lipid
extracts from PDT-treated HaCaT cells
did not induce IL-8 production (data not
shown) nor intracellular calcium mobi-
lization responses in PAF-R-negative
KBM cells (Supplementary Figure S2
online). To structurally define the PAF-
R ligands generated by PDT in HaCaT
cells, we used mass spectrometry with
deuterium-labeled internal standards as
per our previously published methodol-
ogy (Yao et al., 2012). As shown in
Figure 1c, we noted approximately 3-
fold increased levels of sn-1 C-16 and
C-18 PAF species in PDT-treated cells.
However, unlike other classic pro-oxi-
dative stressors such as UVB, PDT did
not identify increased levels of Ox-GPCs
(see Supplementary Methods online for
all GPC species monitored). These find-
ings suggest that PDT-generated PAF-R
ligands are enzymatically produced,
and not via ROS-mediated nonenzy-
matic processes. Consistent with this
result, pretreatment of HaCaT cells with
antioxidants vitamin C or N-acetylcys-
teine at doses that attenuate UVB-gen-
erated PAF-R agonists (Yao et al., 2012)
did not block PDT-generated PAF-R
agonistic activity (see Supplementary
Figure S3 online).
Studies have shown that topical PDT
induces systemic immunosuppression
(Hayami et al., 2007). As PDT induces
the production of PAF in vitro, we
assessed whether PDT-induced syste-
mic immunosuppression is through
PAF-R engagement. To this purposeAccepted article preview online 22 July 2014; published online 21 August 2014
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we used a well-established model of
contact hypersensitivity (CHS) to the
chemical DNFB using wild-type (WT)
and Ptafr / mice in studies approved
by our institution’s animal review
committee (see Zhang et al., 2008 for
methods). PDT was performed by
adding 5-ALA (20 mg per mouse) to
the shaved lower back of the mice.
After 4 hours (in the dark), the mice
were anesthetized and part of the
shaved area on the lower back was
exposed to a blue light (20 J cm2).
Five days after PDT, the mice were
sensitized with DNFB topically applied
to the shaved non-PDT-treated upper
back (to test for systemic immuno-
suppression) and challenged 9 days
later with DNFB applied to the ears.
The intensity of the immune response to
DNFB was measured by the change in
ear thickness prior and 24 hours after
challenge. As positive controls for imm-
unosuppression, one group was injected
with CPAF (250 ng per mouse,
intraperitoneal injection) and the other
injected with histamine (250mg per
mouse, subcutaneous injection) 5 days
prior to sensitization with DNFB. As
shown in Figure 2, PDT significantly
inhibited CHS reactions in WT but not
in PAF-R-deficient mice. Injection of
CPAF had the same effect as PDT,
inducing immunosuppression only in
WT mice. Similar to what we observed
in vitro, 5-ALA only and light only were
not able to inhibit CHS reactions in WT
mice as observed for PDT (5-ALAþ
light; data not shown).
Together, these results show that PDT
induces the local generation of PAF,
which leads to systemic immuno-
suppression. The mechanisms involved
are yet to be described, but studies
suggest the involvement of cyclooxy-
genase-2 (COX-2)/PGE2, mast cells,
regulatory T cells, and IL-10 in PAF-R-
mediated systemic immunosuppression
(Walterscheid et al., 2002; Wolf et al.,
2006; Zhang et al., 2008; Sahu et al.,
2012; Sahu et al., 2013). The finding
that PDT induces systemic immuno-
suppression via PAF-R signaling could
provide the impetus for testing the
ability of inhibitors of this pathway
(e.g., COX-2 inhibitors) to improve the
effectiveness or limit the side effects of
this therapy.
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Figure 1. PDT induces PAF-R ligand formation in human HaCaT keratinocytes. (a) HaCaT cells were
incubated with 5-ALA followed by exposure to a blue LED light source alone (10 or 20 J cm2) or both
20 J cm 2þ5-ALA (PDT). Controls consisted of HaCaT cells exposed to 5-ALA alone, to blue light alone,
or to the lipid extract vehicle (ethanol). Lipid extracts were obtained immediately following treatment and
normalized to cell number (2.5106 cells), and then added to KBP cells. After 6 hours, IL-8 was quantified
as a measure of PAF-R agonistic activity. One group of KBP cells was treated with 100 nM CPAF as a
positive control and the other group with 0.5% ethanol vehicle. (b) For the time course analysis of PDT-
generated PAF-R ligand formation, after PDT (10 or 20 J cm2), cells were incubated for 0, 30, or
60 minutes at 37 1C, and lipid extracts obtained and IL-8 levels compared with sham-treated cells for
60 minutes. Results in a and b are expressed as the percentage of IL-8 relative to amounts induced by
CPAF. (c) Lipid extracts from sham- versus PDT-treated HaCaT at time 0 were analyzed by liquid
chromatography–mass spectrometry and expressed as fold increase relative to sham. The data are
mean±SE from at least three independent experiments. * Denotes statistically significant (Po0.05)
changes from vehicle or sham. 5-ALA, 5-aminolevulinic acid; CPAF, 1-hexadecyl-2-N-methylcarbamoyl
glycerophosphocholine; GPC, glycerophosphocholine; KBP, platelet-activating factor receptor-expressing
human epithelial KB cell line; PAF-R, platelet-activating factor receptor; PDT, photodynamic therapy.
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Figure 2. PDT inhibits CHS to DNFB in a PAF-R-dependent manner. For PDT treatment, groups of five to
eight WT and PAF-R KO (Ptafr / ) mice were treated topically with 5-aminolevulinic acid on the shaved
lower back. After 4 hours, the shaved lower back area was exposed to blue light (20 J cm 2). Other groups of
mice were injected with CPAF (250 ng per mouse, intraperitoneal injection) or histamine (250mg per mouse,
subcutaneous injection). Five days after treatment, the shaved upper back of all mice was painted with
DNFB. After 9 days, the ear thickness was measured, one ear treated with DNFB the other with vehicle, and
measured again after 24 hours. Results are mean±SE percentage of change in the ear thickness relative to
sham group from three separate experiments using a minimum of five mice per experimental group. * And #
denote statistically significant (Po0.05) changes from sham (* for WT and # for PAF-R KO). CHS, contact
hypersensitivity; CPAF, 1-hexadecyl-2-N-methylcarbamoyl glycerophosphocholine; KO, knock out; PAF-R,
platelet-activating factor receptor; PDT, photodynamic therapy; WT, wild type.
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